Brief: Soligenix Announces Scheduling Of Type A Meeting With U.S. FDA For Hybryte New Drug Application

Soligenix

03/04/2023 12:34

April 3 (Reuters) - Soligenix Inc  SNGX.O :
    * SOLIGENIX ANNOUNCES SCHEDULING OF TYPE A MEETING WITH THE
U.S.
FDA FOR HYBRYTE™ NEW DRUG APPLICATION IN THE TREATMENT OF
CUTANEOUS T-CELL LYMPHOMA
    * SOLIGENIX INC - UPDATE ON FDA MEETING OUTCOME EXPECTED BY
END OF
APRIL

Source text for Eikon:  ID:nPn8WCtnNa 
Further company coverage:  SNGX.O 

 ((reuters.briefs@thomsonreuters.com;))